Wild Type and Gain of Function Mutant TP53 can Regulate the Sensitivity of Pancreatic Cancer Cells to Chemotherapeutic Drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 Pathway Inhibitors, Nutraceuticals and Alter Metabolic Properties
Author
McCubrey, James A.; Meher, Akshaya K.; Akula, Shaw M.; Abrams, Stephen L.; Steelman, Linda S.; LaHair, Michelle M.; Franklin, Richard A.; Martelli, Alberto M.; Ratti, Stefano; Cocco, Lucio; Barbaro, Fulvio; Duda, Przemysław; Gizak, Agnieszka
Subject
Date
2022-04-27
Citation:
APA:
McCubrey, James A., & Meher, Akshaya K., & Akula, Shaw M., & Abrams, Stephen L., & Steelman, Linda S., & LaHair, Michelle M., & Franklin, Richard A., & Martelli, Alberto M., & Ratti, Stefano, & Cocco, Lucio, & Barbaro, Fulvio, & Duda, Przemysław, & Gizak, Agnieszka. (April 2022).
Wild Type and Gain of Function Mutant TP53 can Regulate the Sensitivity of Pancreatic Cancer Cells to Chemotherapeutic Drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 Pathway Inhibitors, Nutraceuticals and Alter Metabolic Properties.
,
(),
-
. Retrieved from
http://hdl.handle.net/10342/11681
MLA:
McCubrey, James A., and Meher, Akshaya K., and Akula, Shaw M., and Abrams, Stephen L., and Steelman, Linda S., and LaHair, Michelle M., and Franklin, Richard A., and Martelli, Alberto M., and Ratti, Stefano, and Cocco, Lucio, and Barbaro, Fulvio, and Duda, Przemysław, and Gizak, Agnieszka.
"Wild Type and Gain of Function Mutant TP53 can Regulate the Sensitivity of Pancreatic Cancer Cells to Chemotherapeutic Drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 Pathway Inhibitors, Nutraceuticals and Alter Metabolic Properties". .
. (),
April 2022.
November 30, 2023.
http://hdl.handle.net/10342/11681.
Chicago:
McCubrey, James A. and Meher, Akshaya K. and Akula, Shaw M. and Abrams, Stephen L. and Steelman, Linda S. and LaHair, Michelle M. and Franklin, Richard A. and Martelli, Alberto M. and Ratti, Stefano and Cocco, Lucio and Barbaro, Fulvio and Duda, Przemysław and Gizak, Agnieszka,
"Wild Type and Gain of Function Mutant TP53 can Regulate the Sensitivity of Pancreatic Cancer Cells to Chemotherapeutic Drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 Pathway Inhibitors, Nutraceuticals and Alter Metabolic Properties," , no.
(April 2022),
http://hdl.handle.net/10342/11681 (accessed
November 30, 2023).
AMA:
McCubrey, James A., Meher, Akshaya K., Akula, Shaw M., Abrams, Stephen L., Steelman, Linda S., LaHair, Michelle M., Franklin, Richard A., Martelli, Alberto M., Ratti, Stefano, Cocco, Lucio, Barbaro, Fulvio, Duda, Przemysław, Gizak, Agnieszka.
Wild Type and Gain of Function Mutant TP53 can Regulate the Sensitivity of Pancreatic Cancer Cells to Chemotherapeutic Drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 Pathway Inhibitors, Nutraceuticals and Alter Metabolic Properties. .
April 2022;
():
.
http://hdl.handle.net/10342/11681. Accessed
November 30, 2023.
Collections